Kiora and Théa Open Innovation Enter Partnership to Develop and Commercialize KIO-301

Pipeline

We’re excited about the products we have in the pipeline and the impact they will have on patients.

Product Indication Preclinical Phase One Phase Two Phase Three
Retinal Disease Programs
KIO-301 (Intravitreal) Retinitis Pigmentosa
 
 
 
 
Choroideremia
 
 
 
 
Stargardt Disease
 
 
 
 
KIO-104 (Intravitreal) Posterior Non-Infectious Uveitis
 
 
 
 
KIO-301 received Orphan Drug Designation from the FDA – March 2022.
KIO-104 received Orphan Drug Designation (EU) – May 2015.
NEWS
Loading RSS Feed